Ro60 was originally identified as a soluble antigen targeted by autoantibodies from patients with autoimmune rheumatic diseases; systemic lupus erythematosus (SLE) and Sjögren’s syndrome [107, 108]. The gene discussed is RO60; the disease is systemic lupus erythematosus.